Antidepressant effect of ketamine, a N-methyl-D-aspartate (NMDA) glutamate receptor antagonist, in the therapy of treatment-resistant depression;Zastosowanie antagonisty receptorów NMDA (N-metylo-D-asparaginianu)- ketaminy w leczeniu depresji lekoopornej

Psychiatria Polska

Volumn 46, Issue 2, 2012, Pages 283-294

  Gosek, Paweł ^a   Chojnacka, Magdalena ^a   Bieńkowski, Przemysław ^b   Świȩcicki, Łukasz ^a  

^a Instytut Psychiatrii i Neurologii II Klinika Psychiatryczna Warszawa   (Poland)

^b Zakład Farmakologii I Fizjologii Układu Nerwowego IPiN W Warszawie ^*  (Poland)

Author keywords

Ketamine; Therapy; Treatment resistant depression

Indexed keywords

GLUTAMIC ACID; KETAMINE;

HUMAN; MAJOR DEPRESSION; MENTAL PATIENT; REVIEW; TREATMENT RESISTANT DEPRESSION; UNSPECIFIED SIDE EFFECT;

ANTIDEPRESSIVE AGENTS; COGNITION; DEPRESSIVE DISORDER, TREATMENT-RESISTANT; HUMANS; KETAMINE; RECEPTORS, N-METHYL-D-ASPARTATE;

EID: 84861538240     PISSN: 00332674     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (29)

1. Murray CJ, Lopez AD. Evidence-based health policy-lessons from the Global Burden of Disease Study. Science 1996; 274: 740-743. (Pubitemid 26398244)
2. Little A. Treatment-resistant depression. Am. Fam. Phys. 2009; 80 (2): 167-172.
3. Charakterystyka produktu leczniczego Ketanest 2008-02-29.
4. Smith DJ, Azzaro AJ, Zaldivar SB, Palmer S, Lee HS. Properties of the optical isomers and metabolites of ketamine on the high affinity transport and catabolism of monoamines. Neuropharmacol. 1981; 20 (4): 391-396. (Pubitemid 11143399)
5. Zarate CA Jr, Du J, Quiroz J i in. Regulation of cellular plasticity cascades in the pathophysiology and treatment of mood disorders: role of the glutamatergic system. An. NY Acad. Sc. 2003; 1003: 273-291. (Pubitemid 38083062)
6. Maeng S, Zarate CA Jr. The role of glutamate in mood disorders: results from the ketamine in major depression study and the presumed cellular mechanism underlying its antidepressant effects. Curr. Psychiatry Rep. 2007; 9 (6): 467-474. (Pubitemid 350284937)
7. Ferguson JM, Shingleton RN. An open-label, flexible-dose study of memantine in major depressive disorder. Clin. Neuropharmacol. 2007; 30 (3): 136-144. (Pubitemid 46871863)
8. Keck PE Jr, Hsu HA, Papadakis K, Russo J Jr. Memantine efficacy and safety in patients with acute mania associated with bipolar I disorder: a pilot evaluation. Clin. Neuropharmacol. 2009; 32 (4): 199-204.
9. Longstaff A. Krótkie wykłady: neurobiologia. Warszawa: PWN; 2009.
10. Altamura C, Maes M, Dai J, Meltzer HY. Plasma concentrations of excitatory amino acids, serine, glycine, taurine and histidine in major depression. Eur. Neuropsychopharmacol. 1995; 5 (supl.): 71-75.
11. Beneyto M, Kristiansen LV, Oni-Orisan A, McCullumsmith RE, Meador-Woodruff JH. Abnormal glutamate receptor expression in the medial temporal lobe in schizophrenia and mood disorders. Neuropsychopharmacol. 2007; 32: 1888-1902. (Pubitemid 47258508)
12. Kendell SF, Krystal JH, Sanacora G. GABA and glutamate systems as therapeutic targets in depression and mood disorders. Expert Opin. Ther. Targets 2005; 9 (1): 153-168. (Pubitemid 40331202)
13. Machado-Vieira R, Yuan P, Brutsche N, DiazGranados N, Luckenbaugh D, Manji HK, Zarate CA Jr. Brain-derived neurotrophic factor and initial antidepressant response to an N-methyl-D-aspartate antagonist. J. Clin. Psychiatry 2009; 70 (12): 1662-1666.
14. Tordera RM, PeiQ, Sharp T. Evidence for increased expression of the vesicular glutamate transporter, VGLUT1, by a course of antidepressant treatment. J. Neurochem. 2005; 94: 875-883. (Pubitemid 41170576)
15. Li N, Lee B, Liu RJ, Banasr M, Dwyer JM, Iwata M, Li XY, Aghajanian G, Duman RS. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA. Science 2010; 329 (5994): 959-964.
16. Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS, Krystal JH. Antidepressant effects of ketamine in depressed patients. Biol. Psychiatry 2000; 47 (4): 351-354. (Pubitemid 30109248)
17. Zarate CA Jr, Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA, Charney DS, Manji HK. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch. Gen. Psychiatry 2006; 63 (8): 856-864. (Pubitemid 44188478)
18. aan het Rot M, Collins KA, Murrough JW, Perez AM, Reich DL, Charney DS, Mathew SJ. Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression. Biol. Psychiatry 2010; 67 (2): 139-145.
19. Diazgranados N, Ibrahim L, Brutsche NE, Newberg A, Kronstein P, Khalife S, Kammerer WA, Quezado Z, Luckenbaugh DA, Salvadore G, Machado-Vieira R, Manji HK, Zarate CA Jr. A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression. Arch. Gen. Psychiatry 2010; 67 (8): 793-802.
20. Paslakis G, Gilles M, Meyer-Lindenberg A, Deuschle M. Oral administration of the NMDA receptor antagonist S-ketamine as add-on therapy of depression: a case series. Pharmacopsychiatry 2010; 43 (1): 33-35.
21. Stefanczyk-Sapieha L, Oneschuk D, Demas M. Intravenous ketamine "burst" for refractory depression in a patient with advanced cancer. J. Palliat. Med. 2008; 11 (9): 1268-1271.
22. Ostroff R, Gonzales M, Sanacora G. Antidepressant effect of ketamine during ECT. Am. J. Psychiatry 2005; 162 (7): 1385-1386.
23. Correll GE, Futter GE. Two case studies of patients with major depressive disorder given low-dose (subanesthetic) ketamine infusions. Pain Med. 2006; 7 (1): 92-95. (Pubitemid 43337717)
24. Paul R, Schaaff N, Padberg F, Möller HJ, Frodl T. Comparison of racemic ketamine and S-ketamine in treatment-resistant major depression: report of two cases. World J. Biol. Psychiatry 2009; 10 (3): 241-244.
25. Liu J, Ji XQ, Zhu XZ. Comparison of psychic emergence reactions after (/)-ketamine and ()-ketamine in mice. Life Sc. 2006; 78: 1839-1844.
26. Kohrs R, Durieux ME. Ketamine: teaching an old drug new tricks. Anesth. Analg. 1998; 87 (5): 1186-1193. (Pubitemid 28501183)
27. Strayer RJ, Nelson LS. Adverse events associated with ketamine for procedural sedation in adults. Am. J. Emerg. Med. 2008; 26 (9): 985-1028.
28. Diazgranados N, Ibrahim LA, Brutsche NE, Ameli R, Henter ID, Luckenbaugh DA, Machado- Vieira R, Zarate CA Jr. Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatment-resistant major depressive disorder. J. Clin. Psychiatry 2010; 71 (12): 1605-11. Epub. 2010, Jul. 13.
29. Price RB, Nock MK, Charney DS, Mathew SJ. Effects of intravenous ketamine on explicit and implicit measures of suicidality in treatment-resistant depression. Biol. Psychiatry 2009; 66 (5): 522-526. Epub. 2009, Jul. 9.